Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies†
Corresponding Author
Micha MM Wilhelmus
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Neuroscience Campus Amsterdam (NCA), VU University Medical Center, Department of Anatomy and Neurosciences, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.Search for more papers by this authorMieke de Jager
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorAnnemieke JM Rozemuller
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
Search for more papers by this authorJohn Brevé
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorJohn GJM Bol
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorRichard L Eckert
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, USA
Search for more papers by this authorBenjamin Drukarch
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorCorresponding Author
Micha MM Wilhelmus
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Neuroscience Campus Amsterdam (NCA), VU University Medical Center, Department of Anatomy and Neurosciences, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.Search for more papers by this authorMieke de Jager
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorAnnemieke JM Rozemuller
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
Search for more papers by this authorJohn Brevé
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorJohn GJM Bol
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorRichard L Eckert
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, USA
Search for more papers by this authorBenjamin Drukarch
Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, The Netherlands
Search for more papers by this authorNo conflicts of interest were declared.
Abstract
Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies. Neurodegeneration observed in these diseases is linked to neuronal fibrillary hyperphosphorylated tau protein inclusions. Transglutaminases (TGs) are inducible enzymes, capable of modifying conformational and/or structural properties of proteins by inducing molecular cross-links. Both transglutaminase 1 (TG1) and transglutaminase 2 (TG2) are abundantly expressed in the brain and are associated with fibrillary hyperphosphorylated tau protein inclusions in neurons of AD, so-called neurofibrillary tangles (NFTs). However, other data obtained by our group suggested that tau pathology in the brain may be primarily related to TG1 and not to TG2 activity. To obtain more information on this issue, we set out to investigate the association of TG1, TG2, and TG-catalysed cross-links with fibrillary hyperphosphorylated tau inclusions in tauopathies other than AD, using immunohistochemistry. We found strong TG1 and TG-catalysed cross-link staining in neuronal tau inclusions characteristic of PSP, FTDP-17 with mutations in the tau gene (FTDP-17T), and PiD brain, whereas, in contrast to AD, TG2 was only rarely observed in these inclusions. Furthermore, using a biochemical approach, we demonstrated that tau is a substrate for TG1-mediated cross-linking. Interestingly, we found co-localization of the TG1 activator, tazarotene-induced gene 3 (TIG3), in the neuronal tau inclusions of PSP, FTDP-17T, and PiD, but not in NFTs of AD cases, indicating that these tau-containing protein aggregates are not identical. We conclude that TG1-catalysed cross-linking, regulated by TIG3, might play an important role in the formation of neuronal tau inclusions in PSP, FTDP-17T, and PiD brain. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Supporting Information
Filename | Description |
---|---|
path_2984_sm_supportinginformations.doc67.5 KB | Supporting Information: Table S1. Patient characteristics. Table S2. Primary antibodies used in this study. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Brion JP, Flament-Durand J, Dustin P. Alzheimer's disease and tau proteins. Lancet 1986; 2: 1098.
- 2Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084–6089.
- 3Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998; 8: 425–427.
- 4Nukina N, Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 1986; 99: 1541–1544.
- 5Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 2006; 26: 457–470.
- 6Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519–526.
- 7Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993; 16: 460–465.
- 8Biernat J, Mandelkow EM, Schroter C, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 1992; 11: 1593–1597.
- 9Trojanowski JQ, Lee VM. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J 1995; 9: 1570–1576.
- 10Kowall NW, Kosik KS. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann Neurol 1987; 22: 639–643.
- 11Norlund MA, Lee JM, Zainelli GM, et al. Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 1999; 851: 154–163.
- 12Singer SM, Zainelli GM, Norlund MA, et al. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem Int 2002; 40: 17–30.
- 13Zainelli GM, Ross CA, Troncoso JC, et al. Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol 2003; 62: 14–24.
- 14Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994; 91: 7787–7791.
- 15Kim SY, Grant P, Lee JH, et al. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 1999; 274: 30 715–30 721.
- 16Eckert RL, Sturniolo MT, Broome AM, et al. Transglutaminase function in epidermis. J Invest Dermatol 2005; 124: 481–492.
- 17Fesus L. Biochemical events in naturally occurring forms of cell death. FEBS Lett 1993; 328: 1–5.
- 18Wilhelmus MM, van Dam AM, Drukarch B. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol 2008; 585: 464–472.
- 19Lorand L, Conrad SM. Transglutaminases. Mol Cell Biochem 1984; 58: 9–35.
- 20Muma NA. Transglutaminase is linked to neurodegenerative diseases. J Neuropathol Exp Neurol 2007; 66: 258–263.
- 21Segers-Nolten I, Wilhelmus MM, Veldhuis G, et al. Tissue transglutaminase modulates α-synuclein oligomerization. Protein Sci 2008; 17: 1395–1402.
- 22Wilhelmus MM, Verhaar R, Andringa G, et al. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 2011; 21: 130–139.
- 23Wilhelmus MM, Grunberg SC, Bol JG, et al. Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol 2008; 19: 612–622.
- 24Dudek SM, Johnson GV. Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J Neurochem 1993; 61: 1159–1162.
- 25Dudek SM, Johnson GV. Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 1994; 651: 129–133.
- 26Wilhelmus MM, Verhaar R, Bol JG, et al. Novel role of transglutaminase 1 in corpora amylacea formation? Neurobiol Aging 2011; 32: 845–856.
- 27Verhaar R, Jongenelen CA, Gerard M, et al. Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 2011; 58: 785–793.
- 28DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A 1998; 95: 14 811–14 815.
- 29Jans R, Sturniolo MT, Eckert RL. Localization of the TIG3 transglutaminase interaction domain and demonstration that the amino-terminal region is required for TIG3 function as a keratinocyte differentiation regulator. J Invest Dermatol 2008; 128: 517–529.
- 30Sturniolo MT, Dashti SR, Deucher A, et al. A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J Biol Chem 2003; 278: 48 066–48 073.
- 31Sturniolo MT, Chandraratna RA, Eckert RL. A novel transglutaminase activator forms a complex with type 1 transglutaminase. Oncogene 2005; 24: 2963–2972.
- 32Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479–486.
- 33Halverson RA, Lewis J, Frausto S, et al. Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 2005; 25: 1226–1233.
- 34Johnson TS, El-Koraie AF, Skill NJ, et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003; 14: 2052–2062.
- 35Sakai M, Austin J, Witmer F, et al. Studies of corpora amylacea. I. Isolation and preliminary characterization by chemical and histochemical techniques. Arch Neurol 1969; 21: 526–544.
- 36Zemaitaitis MO, Kim SY, Halverson RA, et al. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 2003; 62: 173–184.
- 37Vandrovcova J, Anaya F, Kay V, et al. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr Alzheimer Res 2010; 7: 726–734.
- 38Kovari E. Neuropathological spectrum of frontal lobe dementias. Front Neurol Neurosci 2009; 24: 149–159.
- 39Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999; 9: 681–693.
- 40Eckert RL, Sturniolo MT, Jans R, et al. TIG3: a regulator of type I transglutaminase activity in epidermis. Amino Acids 2009; 36: 739–746.
- 41Schmidt ML, Huang R, Martin JA, et al. Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau. J Neuropathol Exp Neurol 1996; 55: 534–539.
- 42Avila J, Lucas JJ, Perez M, et al. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84: 361–384.
- 43Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids 2007; 33: 385–394.
- 44Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184–185.
- 45Cavanagh JB. Corpora-amylacea and the family of polyglucosan diseases. Brain Res Brain Res Rev 1999; 29: 265–295.
- 46Deucher A, Nagpal S, Chandraratna RA, et al. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int J Oncol 2000; 17: 1195–1203.
Note: Reference 46 is cited in the Supporting information to this article.